Novo Nordisk's Obesity Setback: What Kagrama's Miss vs. Zepbound Means for Investors
Source: Motley Fool
2026-03-05 16:25:00 ET
A surprising obesity trial result has shaken confidence in Novo Nordisk (NYSE: NVO) and sharpened the spotlight on Eli Lilly (NYSE: LLY) in this fiercely competitive GLP?1 race. Watch the video below to see what it could mean for investors.
*This video was published on Feb.24, 2026.
Novo Nordisk A/S
NASDAQ: NVO
NVO Trading
-0.43% G/L:
$38.015 Last:
6,640,007 Volume:
$38.39 Open:
NVO Latest News
NVO Stock Data
$220,548,675,000
4,194,421,000
N/A
749
N/A
Biotechnology & Life Sciences
Healthcare
DK
Bagsvaerd
